Your browser doesn't support javascript.
loading
Decreased Risk of Osteoporosis Incident in Subjects Receiving Chinese Herbal Medicine for Sjögren syndrome Treatment: A Retrospective Cohort Study with a Nested Case-Control Analysis.
Yen, Chieh-Tsung; Livneh, Hanoch; Huang, Hua-Lung; Lu, Ming-Chi; Chen, Wei-Jen; Tsai, Tzung-Yi.
Affiliation
  • Yen CT; Department of Neurology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
  • Livneh H; Rehabilitation Counseling Program, Portland State University, Portland, OR 97207-0751, USA.
  • Huang HL; Department of Rehabilitation, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
  • Lu MC; School of Medicine, Tzu Chi University, Hualien 97004, Taiwan.
  • Chen WJ; Division of Allergy, Immunology and Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
  • Tsai TY; Department of Chinese Medicine, Dalin Tzuchi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
Pharmaceuticals (Basel) ; 17(6)2024 Jun 06.
Article in En | MEDLINE | ID: mdl-38931412
ABSTRACT
Sjögren syndrome (SS) is a long-lasting inflammatory autoimmune disease that may cause diverse manifestations, particularly osteoporosis. Though usage of Chinese herbal medicine (CHM) can safely manage autoimmune disease and treatment-related symptoms, the relation between CHM use and osteoporosis risk in SS persons is not yet recognized. With that in mind, this population-level nested case-control study aimed to compare the risk of osteoporosis with and without CHM use. Potential subjects aged 20-70 years, diagnosed with SS between 2001 and 2010, were retrieved from a national health claims database. Those diagnosed with osteoporosis after SS were identified and randomly matched to those without osteoporosis. We capitalize on the conditional logistic regression to estimate osteoporosis risk following CHM use. A total of 1240 osteoporosis cases were detected and randomly matched to 1240 controls at a ratio of 11. Those receiving conventional care plus CHM had a substantially lower chance of osteoporosis than those without CHM. Prolonged use of CHM, especially for one year or more, markedly dwindled sequent osteoporosis risk by 71%. Integrating CHM into standard care may favor the improvement of bone function, but further well-designed randomized controlled trials to investigate the possible mechanism are needed.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Pharmaceuticals (Basel) Year: 2024 Document type: Article Affiliation country: Taiwán Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Pharmaceuticals (Basel) Year: 2024 Document type: Article Affiliation country: Taiwán Country of publication: Suiza